Price, clinical utility, and turnaround time of WGS most important aspects. »
05/01/21

Survival estimates generally lower than those reported in pivotal clinical trials. »
01/21/21

Support for further translation of C-terminal Hsp90 inhibitor and mitogen-activated protein kinase pathway inhibitor. »
04/27/21

No difference in risk of 5-year CVM. »
12/01/20

Female patients and those who received chemotherapy less trusting post-treatment. »
03/29/21

Both chemoradiation and thermoradiation benefit significantly from additional treatment with PARP1-i. »
02/15/21

FASN inhibition significantly reduced ERα levels. »
01/27/21

ITIH5 increases sensitivity of SCaBER cells to chemotherapeutical agents. »
03/17/21

CBT associated with lower LFS, OS, and GRFS. »
05/03/21

RAS/BRAFV600E mutations detected in 54% of cases. »
05/07/21